Furthermore, recent studies have demonstrated that targeting CAIX in combination with chemotherapy or immune checkpoint blockade increases efficacy in several pre-clinical tumor models, including pancreatic cancer, glioblastoma, melanoma and TNBC [24,25,26]. Here, CA9 is linked to glioblastoma.